文献速递肾小球疾病慢性肾脏病

非奈利酮联合SGLT2i治疗IgA肾病的疗效与安全性

Efficacy and safety of finerenone with SGLT2i in IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

该回顾性研究纳入76例经活检证实的IgA肾病患者,分为非奈利酮联合SGLT2i组(n=26)、非奈利酮单药组(n=32)和SGLT2i单药组(n=18),评估3个月和6个月时UPCR和eGFR变化及安全性。结果显示联合治疗降蛋白尿效果优于单药,且肾功能稳定、高钾血症发生率无显著差异。

要点

  • 联合治疗降UPCR幅度更大:3个月40.89%、6个月54.62%,优于单药。

核心结论

  • 非奈利酮联合SGLT2i治疗IgA肾病比单药治疗降蛋白尿更快速、更优,且肾功能稳定、安全性良好。

研究设计与样本

  • 回顾性研究,纳入2023-24年郑州大学第一附属医院76例经活检证实的IgA肾病患者。
  • 分为联合组(n=26)、非奈利酮单药组(n=32)和SGLT2i单药组(n=18)。
  • 评估3个月和6个月时UPCR和eGFR变化,安全性关注高钾血症和治疗中出现的不良事件。

临床怎么用

  • 对IgA肾病患者,非奈利酮联合SGLT2i可能比单药更快、更大幅度降低蛋白尿。
  • 联合治疗期间需监测血钾,但本研究显示高钾血症风险与单药相当。
  • 肾功能在联合治疗中保持稳定,支持其肾脏保护潜力。

局限性

  • 回顾性研究,样本量较小(76例),可能存在选择偏倚。
  • 随访时间较短(6个月),长期疗效和安全性未评估。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to compare the renal protective effects and safety profile of finerenone plus sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy versus monotherapy in patients with immunoglobulin A (IgA) nephropathy. METHODS: The retrospective study evaluated 76 patients with biopsy-proven IgA nephropathy at the First Affiliated Hospital of Zhengzhou University (2023-24). Participants were divided into three groups: finerenone plus SGLT2i group (n = 26), finerenone monotherapy group (n = 32) and SGLT2i monotherapy group (n = 18). Changes in urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate at 3 and 6 months were evaluated. Safety assessments focused on hyperkalemia incidence and treatment-emergent adverse events. RESULTS: The combination therapy demonstrated superior proteinuria reduction compared with monotherapies, with median UPCR reductions of 40.89% at Month 3 and 54.62% at Month 6 versus 23.72%/30.88% (finerenone) and 24.69%/24.69% (SGLT2i) (all P < .05). Significantly more patients achieved ≥50% UPCR reduction in the finerenone plus SGLT2i group at Month 6 (53.8% vs 25.0% and 22.2%, P = .033). Logistic regression analysis demonstrated adjusted odds ratios ranging from 3.87 to 18.90 for finerenone plus SGLT2i therapy achieving ≥50% proteinuria reduction (all P < .05). Renal function parameters remained stable in all treatment groups without significant intergroup differences (all P > .05). The safety profile showed comparable hyperkalemia incidence rates between groups (P = .332). No severe adverse events or treatment withdrawals attributable to hyperkalemia were observed. CONCLUSION: Our study shows that combined finerenone-SGLT2i therapy has a more rapid and superior proteinuria reduction versus monotherapy in IgA nephropathy, with preserved renal function and good safety.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Guo Y, Zhao S, Dong Y, et al. Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 41206667. doi:10.1093/ndt/gfaf244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。